New Issue: Living Cell raises A$3.04 million from private placement of stock

By Sheri Kasprzak

New York, Jan. 11 - Living Cell Technologies Ltd. said it has completed a private placement for A$3,035,203.

The company sold 14,269,283 shares at A$0.205 each to a group of U.S.-based institutional investors and 500,000 shares at A$0.22 each to an Australian investor.

Hunter Capital International was the placement agent.

Proceeds from the deal will be used to help fund clinical trials of NeurotrophinCell, the company's treatment for Huntington's disease.

Based in Victoria, Australia, Living Cell develops live cell therapies used to replace or repair damaged human tissues.

Issuer:	Living Cell Technologies Ltd.
Issue:	Stock
Amount:	A$3,035,203
Shares:	14,769,283
Price:	A$0.205 for 14,269,283 shares; A$0.22 for 500,000 shares
Warrants:	No
Placement agent:	Hunter Capital International
Settlement date:	Jan. 11
Stock price:	A$0.21 at close Jan. 11
Ticker:	Berlin: LHI

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.